论文部分内容阅读
目的探讨重组人表皮生长因子凝胶(rhEGF)联合莫匹罗星交替使用治疗深Ⅱ°烧伤的临床疗效。方法选取我院收治的600例深Ⅱ°烧伤患者为研究对象,采用rhEGF联合莫匹罗星交替使用疗法进行治疗的300例患者为表皮生长因子组,采用湿润烧伤膏外涂暴露疗法治疗的300例患者为烧伤膏组。比较两组患者的临床治疗效果。结果表皮生长因子组不同时间段创面愈合情况明显优于烧伤膏组(P<0.05);表皮生长因子组全身创面愈合时间为(13.79±2.46)d,明显短于烧伤膏组的(22.73±4.92)d(P<0.05);表皮生长因子组创面瘢痕发生率为19.67%,明显低于烧伤膏组的39.00%(P<0.05)。结论 rhEGF联合莫匹罗星交替使用治疗深Ⅱ°烧伤创面愈合时间短,瘢痕形成率低。
Objective To investigate the clinical efficacy of recombinant human epidermal growth factor gel (rhEGF) combined with mupirocin in the treatment of deep Ⅱ ° burns. Methods A total of 600 patients with deep Ⅱ ° burns treated in our hospital were enrolled in this study. 300 patients treated with rhEGF combined with mupirocin alternate therapy were epidermal growth factor (EGF) group. 300 Cases of patients with burn cream group. The clinical effects of the two groups were compared. Results The wound healing in epidermal growth factor group was significantly better than that in burn ointment group at different time points (P <0.05). The wound healing time of epidermal growth factor group was (13.79 ± 2.46) d, which was significantly shorter than that of burn burn group (22.73 ± 4.92 ) d (P <0.05). The incidence of wounds in the epidermal growth factor group was 19.67%, which was significantly lower than that in the burn group (39.00%, P <0.05). Conclusion The combination of rhEGF and mupirocin for the treatment of deep Ⅱ ° burn wounds has short healing time and low scar formation rate.